Drug Type Antibody drug conjugate (ADC) |
Synonyms AT 401, AT401 |
Target |
Action inhibitors, antagonists |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Preclinical | United States | 02 Aug 2024 |






